AstraZeneca's Lupus Treatment Fails in Final-Stage Study
- Inflammation blocker had been seen as rare new treatment
- Drugmaker to evaluate data from trial later this year
Photographer: Simon Dawson/Bloomberg
This article is for subscribers only.
AstraZeneca Plc’s experimental treatment for lupus failed to meet the goal of a late-stage trial, a blow to the drugmaker’s efforts to develop a rare new therapy for the potentially life-threatening disease.
Patients with moderate to severe cases of lupus who got the drug, called anifrolumab, didn’t see a statistically significant reduction in disease activity compared with those who received a placebo in the yearlong study, Cambridge, England-based AstraZeneca said Friday in a statement.